Leflunomid és biológiai terápia együttadasa rheumatoid arthritisben

Translated title of the contribution: Combination of leflunomide and biologic agents in the treatment of rheumatoid arthritis

Research output: Contribution to journalArticle

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that leads to progressive joint destruction, functional disability and extra-articular complications. The initial approach to treatment of RA begins with the diagnosis, estimation of patient's prognosis and the implementation of a therapeutic plan. Most important is early and aggressive treatment with disease-modifying antirheumatic drugs (DMARD5). Among the different protocols, combination therapies including methotrexate and! or biologics seem to be more effective than monotherapies. Biological therapies introduced in recent years opened a new era in the treatment of RA. Randomized, controlled trials have demonstrated that the addition of methotrexate to biologic agents, such as tumor necrosis factor alpha (TNF-a) inhibitors generally increases their ability to retard structural damage, reduce disease activity and improve function. However, not all patients tolerate or respond to methotrexate. One of the most common used alternative DMARDs is leflunomide. Earlier several smaller retrospective studies, later prospective cohort studies, and finally two new population- based longitudinal observational studies found that the above-mentioned parameters in RA patients treated with anti-TNF agents and leflunomide were similar to those receiving anti-TNF and methotrexate in combination. In addition, there were no significant differences in the frequency of adverse events between the groups. Taken together, teflunomide should be regarded as an effective and safe alternative in the treatment of rheumatoid arthritis.

Original languageHungarian
Pages (from-to)383-388
Number of pages6
JournalLege Artis Medicinae
Volume19
Issue number6-7
Publication statusPublished - Jul 2009

Fingerprint

leflunomide
Biological Factors
Rheumatoid Arthritis
Methotrexate
Antirheumatic Agents
Therapeutics
Joints
Biological Therapy
Biological Products
Autoimmune Diseases
Observational Studies
Longitudinal Studies
Cohort Studies
Randomized Controlled Trials
Retrospective Studies
Tumor Necrosis Factor-alpha
Prospective Studies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Leflunomid és biológiai terápia együttadasa rheumatoid arthritisben. / Szűcs, G.

In: Lege Artis Medicinae, Vol. 19, No. 6-7, 07.2009, p. 383-388.

Research output: Contribution to journalArticle

@article{209191bd55df4e78b983ee3485ca2ec1,
title = "Leflunomid {\'e}s biol{\'o}giai ter{\'a}pia egy{\"u}ttadasa rheumatoid arthritisben",
abstract = "Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that leads to progressive joint destruction, functional disability and extra-articular complications. The initial approach to treatment of RA begins with the diagnosis, estimation of patient's prognosis and the implementation of a therapeutic plan. Most important is early and aggressive treatment with disease-modifying antirheumatic drugs (DMARD5). Among the different protocols, combination therapies including methotrexate and! or biologics seem to be more effective than monotherapies. Biological therapies introduced in recent years opened a new era in the treatment of RA. Randomized, controlled trials have demonstrated that the addition of methotrexate to biologic agents, such as tumor necrosis factor alpha (TNF-a) inhibitors generally increases their ability to retard structural damage, reduce disease activity and improve function. However, not all patients tolerate or respond to methotrexate. One of the most common used alternative DMARDs is leflunomide. Earlier several smaller retrospective studies, later prospective cohort studies, and finally two new population- based longitudinal observational studies found that the above-mentioned parameters in RA patients treated with anti-TNF agents and leflunomide were similar to those receiving anti-TNF and methotrexate in combination. In addition, there were no significant differences in the frequency of adverse events between the groups. Taken together, teflunomide should be regarded as an effective and safe alternative in the treatment of rheumatoid arthritis.",
keywords = "Biological therapy, Leflunomide, Rheumatoid arthritis, TNF-a inhibitor",
author = "G. Szűcs",
year = "2009",
month = "7",
language = "Hungarian",
volume = "19",
pages = "383--388",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "6-7",

}

TY - JOUR

T1 - Leflunomid és biológiai terápia együttadasa rheumatoid arthritisben

AU - Szűcs, G.

PY - 2009/7

Y1 - 2009/7

N2 - Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that leads to progressive joint destruction, functional disability and extra-articular complications. The initial approach to treatment of RA begins with the diagnosis, estimation of patient's prognosis and the implementation of a therapeutic plan. Most important is early and aggressive treatment with disease-modifying antirheumatic drugs (DMARD5). Among the different protocols, combination therapies including methotrexate and! or biologics seem to be more effective than monotherapies. Biological therapies introduced in recent years opened a new era in the treatment of RA. Randomized, controlled trials have demonstrated that the addition of methotrexate to biologic agents, such as tumor necrosis factor alpha (TNF-a) inhibitors generally increases their ability to retard structural damage, reduce disease activity and improve function. However, not all patients tolerate or respond to methotrexate. One of the most common used alternative DMARDs is leflunomide. Earlier several smaller retrospective studies, later prospective cohort studies, and finally two new population- based longitudinal observational studies found that the above-mentioned parameters in RA patients treated with anti-TNF agents and leflunomide were similar to those receiving anti-TNF and methotrexate in combination. In addition, there were no significant differences in the frequency of adverse events between the groups. Taken together, teflunomide should be regarded as an effective and safe alternative in the treatment of rheumatoid arthritis.

AB - Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that leads to progressive joint destruction, functional disability and extra-articular complications. The initial approach to treatment of RA begins with the diagnosis, estimation of patient's prognosis and the implementation of a therapeutic plan. Most important is early and aggressive treatment with disease-modifying antirheumatic drugs (DMARD5). Among the different protocols, combination therapies including methotrexate and! or biologics seem to be more effective than monotherapies. Biological therapies introduced in recent years opened a new era in the treatment of RA. Randomized, controlled trials have demonstrated that the addition of methotrexate to biologic agents, such as tumor necrosis factor alpha (TNF-a) inhibitors generally increases their ability to retard structural damage, reduce disease activity and improve function. However, not all patients tolerate or respond to methotrexate. One of the most common used alternative DMARDs is leflunomide. Earlier several smaller retrospective studies, later prospective cohort studies, and finally two new population- based longitudinal observational studies found that the above-mentioned parameters in RA patients treated with anti-TNF agents and leflunomide were similar to those receiving anti-TNF and methotrexate in combination. In addition, there were no significant differences in the frequency of adverse events between the groups. Taken together, teflunomide should be regarded as an effective and safe alternative in the treatment of rheumatoid arthritis.

KW - Biological therapy

KW - Leflunomide

KW - Rheumatoid arthritis

KW - TNF-a inhibitor

UR - http://www.scopus.com/inward/record.url?scp=69249105955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69249105955&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:69249105955

VL - 19

SP - 383

EP - 388

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 6-7

ER -